| 1. |
- Wolever, Thomas M S, et al.
(författare)
-
Measuring the glycemic index of foods: interlaboratory study.
- 2008
-
Ingår i: The American journal of clinical nutrition. - 0002-9165 .- 1938-3207. ; 87:1
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Many laboratories offer glycemic index (GI) services. OBJECTIVE: We assessed the performance of the method used to measure GI. DESIGN: The GI of cheese-puffs and fruit-leather (centrally provided) was measured in 28 laboratories (n=311 subjects) by using the FAO/WHO method. The laboratories reported the results of their calculations and sent the raw data for recalculation centrally. RESULTS: Values for the incremental area under the curve (AUC) reported by 54% of the laboratories differed from central calculations. Because of this and other differences in data analysis, 19% of reported food GI values differed by >5 units from those calculated centrally. GI values in individual subjects were unrelated to age, sex, ethnicity, body mass index, or AUC but were negatively related to within-individual variation (P=0.033) expressed as the CV of the AUC for repeated reference food tests (refCV). The between-laboratory GI values (mean+/-SD) for cheese-puffs and fruit-leather were 74.3+/-10.5 and 33.2+/-7.2, respectively. The mean laboratory GI was related to refCV (P=0.003) and the type of restrictions on alcohol consumption before the test (P=0.006, r2=0.509 for model). The within-laboratory SD of GI was related to refCV (P<0.001), the glucose analysis method (P=0.010), whether glucose measures were duplicated (P=0.008), and restrictions on dinner the night before (P=0.013, r2=0.810 for model). CONCLUSIONS: The between-laboratory SD of the GI values is approximately 9. Standardized data analysis and low within-subject variation (refCV<30%) are required for accuracy. The results suggest that common misconceptions exist about which factors do and do not need to be controlled to improve precision. Controlled studies and cost-benefit analyses are needed to optimize GI methodology. The trial was registered at clinicaltrials.gov as NCT00260858.
|
|
| 2. |
|
|
| 3. |
- Tampere, M, et al.
(författare)
-
Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses
- 2020
-
Ingår i: Viruses. - : MDPI AG. - 1999-4915. ; 12:12
-
Tidskriftsartikel (refereegranskat)abstract
- Recent RNA virus outbreaks such as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and Ebola virus (EBOV) have caused worldwide health emergencies highlighting the urgent need for new antiviral strategies. Targeting host cell pathways supporting viral replication is an attractive approach for development of antiviral compounds, especially with new, unexplored viruses where knowledge of virus biology is limited. Here, we present a strategy to identify host-targeted small molecule inhibitors using an image-based phenotypic antiviral screening assay followed by extensive target identification efforts revealing altered cellular pathways upon antiviral compound treatment. The newly discovered antiviral compounds showed broad-range antiviral activity against pathogenic RNA viruses such as SARS-CoV-2, EBOV and Crimean-Congo hemorrhagic fever virus (CCHFV). Target identification of the antiviral compounds by thermal protein profiling revealed major effects on proteostasis pathways and disturbance in interactions between cellular HSP70 complex and viral proteins, illustrating the supportive role of HSP70 on many RNA viruses across virus families. Collectively, this strategy identifies new small molecule inhibitors with broad antiviral activity against pathogenic RNA viruses, but also uncovers novel virus biology urgently needed for design of new antiviral therapies.
|
|
| 4. |
- Lightowler, Molly, 1995-
(författare)
-
Investigating polymorphism in small molecules using three-dimensional electron diffraction
- 2022
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- For scientific, regulatory and intellectual property reasons, the discovery and characterisation of polymorphic systems is an integral aspect of the development process of any solid-formulated drug product. Yet, these studies are often hindered by crystal quality and size, poor yields and the generation of mixtures of phases. Three-dimensional electron diffraction (3D ED) is a technique capable of structure determination from individually selected, nanometre-sized crystals. In this thesis, 3D ED is applied to investigate polymorphism in small molecules. The unique advantages of the method are highlighted across numerous studies to demonstrate how 3D ED can broaden the scope of polymorphism discovery and characterisation in the screening and selection of pharmaceutical crystal forms. 3D ED is first applied to reveal that two crystallisation methods believed for 47 years to produce Form δ of the pharmaceutical compound indomethacin result in two different polymorphs, highlighting the power of the method for polymorphism discovery. The polymorphic crystal structures of a small molecule are then determined directly from melt-grown compact spherulites for the first time to show how 3D ED can widen the application of melt crystallisation in polymorph screening, where polycrystalline spherulites are common products. Furthermore, 3D ED is combined with on-the-grid crystallisation and plunge freezing to follow the polymorph evolution of glycine during crystallisation from an aqueous solution to demonstrate the ability of the method to monitor crystallisation processes in situ. The final part of the thesis explores how a high-throughput method combining 3D ED data collection in batch mode with semi-automated data processing can be applied for the phase analysis of complex melt crystallisation products to improve the efficiency and accuracy of polymorph screening.
|
|
